Tag «厄达替尼»

Erdafitinib, エルダフィチニブ ,Эрдафитиниб , إيردافيتينيب , 厄达替尼 ,

It’s only fair to share… Erdafitinib エルダフィチニブ JNJ-42756493 CAS 1346242-81-6 MF, C25H30N6O2, MW 446.54 UNII-890E37NHMV 890E37NHMV 2019/4/12, FDA APPROVED, BALVERSA (Janssen Products LP) Balversa Эрдафитиниб [Russian] [INN] إيردافيتينيب [Arabic] [INN] 厄达替尼 [Chinese] [INN] N‘-(3,5-dimethoxyphenyl)-N‘-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]- [ACD/Index Name] 10147 1346242-81-6 [RN] 890E37NHMV N-(3,5-dimethoxyphenyl)-N’-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine 5SF MFCD28502040 N’-(3,5-dimethoxyphenyl)-N’-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine Erdafitinib is an orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds …